Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Shares Outstanding (Diluted Average) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 158.24% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 158.24% increase, with the full-year FY2024 number at $12.1 million, up 38.61% from a year prior.
  • Shares Outstanding (Diluted Average) was $1.1 million for Q3 2025 at bioAffinity Technologies, down from $24.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $24.0 million in Q2 2025 to a low of $412936.0 in Q3 2024.
  • A 4-year average of $8.6 million and a median of $8.5 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 214.74% in 2023, then tumbled 95.17% in 2024.
  • bioAffinity Technologies' Shares Outstanding (Diluted Average) stood at $4.5 million in 2022, then soared by 94.43% to $8.7 million in 2023, then skyrocketed by 38.61% to $12.1 million in 2024, then tumbled by 91.21% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Shares Outstanding (Diluted Average) are $1.1 million (Q3 2025), $24.0 million (Q2 2025), and $16.3 million (Q1 2025).